NovaBay Pharmaceuticals, Inc. (NBY)
Stock Price:
$1.11 USD
-0.03 (-2.63%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
37.05M |
| Revenue (ttm) |
9.24M |
| Net Income (ttm) |
-9.03M |
| Shares Out |
33.38M |
| EPS (ttm) |
-0.36 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$1.11 |
| Previous Close |
$1.14 |
| Change ($) |
-0.03 |
| Change (%) |
-2.63% |
| Day's Open |
1.12 |
| Day's Range |
1.10 - 1.15 |
| Day's Volume |
1,980,190 |
| 52-Week Range |
0.24 - 1.94 |
More Stats
| Market Cap |
37.05M |
| Enterprise Value |
29.72M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
33.38M |
| Float |
26.27M |
| EPS (basic) |
-0.34 |
| EPS (diluted) |
-0.36 |
| FCF / Share |
-0.16 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.24M |
| Short Ratio |
0.13 |
| Short % of Float |
5.43% |
| Beta |
3.88 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
4.01 |
| PB Ratio |
28.21 |
| Revenue |
9.24M |
| Operating Income |
-6.56M |
| Net Income |
-9.03M |
| Free Cash Flow |
-4.84M |
| Net Cash |
7.33M |
| Net Cash / Share |
0.22 |
| Gross Margin |
52.63% |
| Operating Margin |
-70.98% |
| Profit Margin |
-107.20% |
| FCF Margin |
-52.35% |
| ROA |
-34.02% |
| ROE |
-681.15% |
| ROIC |
-360.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
3.00
Current: $1.11
High
3.00
Target: 3.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 6.60 | 12.51 | 18.23 | 11.90 | 4.38 | 1.05 | 3.48 | 6.95 | 11.02 | 9.75 |
| Revenue Growth | -47.24% | -31.39% | 53.23% | 171.56% | 315.65% | -69.69% | -49.95% | -36.95% | 12.97% | - |
| Gross Profit | 4.86 | 11.01 | 15.45 | 9.43 | 3.12 | 0.57 | 3.32 | 6.94 | 11.02 | 9.75 |
| Operating Income | -9.40 | -7.87 | -7.31 | -10.98 | -21.14 | -16.90 | -15.51 | -8.33 | -4.32 | -4.52 |
| Net Income | -9.66 | -6.55 | -7.40 | -13.15 | -18.97 | -15.19 | -16.04 | -7.03 | -5.09 | -4.31 |
| Shares Outstanding | 21.64 | 16.92 | 15.32 | 9.41 | 2.78 | 1.99 | 1.53 | 1.18 | 1.03 | 0.93 |
| Earnings Per Share | -0.48 | -0.46 | -0.48 | -1.40 | -6.82 | -7.65 | -10.51 | -5.97 | -4.93 | -4.50 |
| Operating Cash Flow | -7.93 | -5.57 | -6.27 | -11.66 | -18.56 | -15.06 | -12.97 | -6.53 | -3.14 | 2.03 |
| Capital Expenditures | -0.02 | -0.04 | -0.24 | -0.16 | -0.09 | 0.06 | -0.14 | -0.14 | -0.12 | -0.20 |
| Free Cash Flow | -7.95 | -5.61 | -6.51 | -11.82 | -18.65 | -15.00 | -13.11 | -6.67 | -3.26 | 1.83 |
| Cash & Equivalents | 6.94 | 3.18 | 3.20 | 9.51 | 2.39 | 5.43 | 13.05 | 16.87 | 14.14 | 12.81 |
| Total Debt | 4.05 | - | - | - | 1.66 | - | - | - | - | 0.11 |
| Net Cash / Debt | 2.89 | 3.18 | 3.20 | 9.51 | 0.73 | 5.43 | 13.05 | 16.87 | 14.14 | 12.70 |
| Assets | 11.22 | 9.36 | 10.08 | 15.38 | 5.08 | 7.54 | 15.65 | 19.24 | 15.96 | 15.52 |
| Liabilities | 10.25 | 4.41 | 7.49 | 8.28 | 10.18 | 5.69 | 7.13 | 5.19 | 6.62 | 5.03 |
| Book Value | 0.97 | 4.95 | 2.59 | 7.10 | -5.10 | 1.85 | 8.52 | 14.05 | 9.34 | 10.49 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
NovaBay Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
26 |
| CEO |
Justin M. Hall |
Stock Information
| Ticker Symbol |
NBY |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: NBY |
| IPO Date |
October 26, 2007 |
Description
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.